RevImmune Announces First Dosage of T-Cell Therapy to Cancer Patient with COVID-19
RevImmune Inc., a biotech company based in Paris, France and Maryland, U.S., has been working with the Cancer Research Institute (CRI) on their T-Cell technology development. The duo announced they have administered the first dose to a patient in a study designed to assess the benefit of interleukin-7 (IL-7) in cancer patients who also have COVID-19.
This project came to light after studies showed that cancer patients with COVID-19 have lowered T-cell levels. The clinical trial aims to evaluate how or if RevImmune’s product CYT107 benefits the 48 people in the trial. CYT107 is a therapeutic form of the master growth factor for human T-cells and could contribute to immune therapies for cancer patients. Regular cancer treatments already contribute to lowered T-cell levels, a sign of a weakened immune system. IL-7 have been shown to rapidly restore functional immune cells. RevImmune is excited to take their research to the next stage.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.org/webinars or contact your usual Swanson Reed representative.
